The ongoing provide constraints for Novo Nordisk’s (NVO) vastly widespread weight reduction remedy, Wegovy, are anticipated to ease as the corporate’s mum or dad, Novo Holdings, agreed to accumulate the U.S. contract producer Catalent (NYSE:CTLT) in a $16.5B deal on Monday.
Shortly after the all-cash deal closes later this 12 months, Novo (NVO) will purchase three CTLT fill-finish websites situated in Anagni, Italy, Bloomington, Indiana, and Brussels, Belgium, from Novo Holdings, which owns ~77% voting shares within the Danish drugmaker.
The transaction is anticipated to assist the corporate step by step develop its filling capability in 2026, Novo (OTCPK:NONOF) stated. Last week, the corporate posted better-than-expected income for 2023, thanks primarily to its diabetes and weight problems franchise led by GLP-1 receptor agonists Ozempic and Wegovy.
The capability is “a key strategic consideration for Novo Nordisk particularly when (…) making sure there is broader rollout for Ozempic and Wegovy,” Kasim Kutay, CEO of Novo Holdings, stated throughout an interview with Reuters.
Thermo Fisher Scientific (TMO), which Novo (NVO) has contracted to fill-finish Wegovy, opened decrease after the announcement, whereas Catalent’s (CTLT) European rival, Lonza (OTCPK:LZAGF) (OTCPK:LZAGY), traded larger.
The deal is unlikely to attract regulatory scrutiny as a result of Novo Holdings is barely promoting three areas from CTLT’s world manufacturing community, which includes roughly 50 websites, Reuters reported, citing an individual conversant in the matter.
The division of property between NVO and its mum or dad also needs to ease regulatory issues a couple of potential affect on Catalent’s (CTLT) different shoppers. “Novo Nordisk will ensure an ordinary transition and will make sure that all the customers will continue to be taken care of,” the supply added.